Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significant association of MMP-2 (-1306C/T) polymorphism with GBM (P = 0.475) was not found, suggesting that MMP-2 (-1306C/T) polymorphism is not associated with increased GBM susceptibility.
|
21483125 |
2011 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DTCM-g also reduces the invasion capacity of all GBM cell lines without alterations in MMP2 and uPa expression.
|
29683097 |
2018 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma T-98G cells expressed only one band corresponding to MMP-2.
|
28112361 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells.
|
11853893 |
2002 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings demonstrated that hCGβ phosphorylated ERK1/2 upregulating MMP-2 expression and activity leading to cell migration and invasion, suggesting that hCGβ, ERK1/2 and MMP-2 are the potential targets to inhibit glioblastoma invasion.
|
23232806 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
|
16598420 |
2006 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
By virtue of its restricted expression in GBM and its role in invasion, Necl-5 may be an attractive target for limiting MMP-2 production in glioblastoma, and therefore limiting dispersal.
|
20680398 |
2011 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association of HSP27 with MMP-2 and MMP-9 proteins along with the identified interacting stretch has the potential to contribute towards drug development to inhibit GBM infiltration and migration.
|
31028823 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, utilizing an array of techniques, including gelatin matrix degradation assays, we show that GBM cell lines can form functional gelatin matrix degrading invadopodia and secrete matrix metalloproteinase 2 (MMP-2), a known invadopodia-associated matrix-degrading enzyme.
|
30219696 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using real-time quantitative reverse transcription-PCR (RT-PCR), gelatin zymography, and immunohistochemistry assays, the expression of the gene encoding matrix metalloproteinase-2 (MMP2) in GBM cell lines grown in vitro or in intracranial xenografts in nude mice was shown to be repressed by either stable or adenoviral-mediated overexpression of PAX6.
|
17047041 |
2006 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MMPs MMP-2 and MMP-9 are associated with the invasion ability of GBM.
|
28454354 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant decline of MMP-9 and MMP-2 secretion in cultured U87MG was detected after incubation with EBB (42.9% and 73.0%, respectively) and EBB + TMZ (38.4% and 68.5%, respectively).
|
25256634 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2.
|
10027400 |
1999 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Zymography analysis also revealed that the activities of MMP-2 and MMP-9 of GBM cells were significantly inhibited in response to 100, 200, or 300 μM naringenin treatment.
|
30431227 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tissue samples from 89 patients diagnosed with diffuse astrocytoma, anaplastic astrocytoma and glioblastoma were stained immunohistochemically using a monoclonal MMP-2 antibody.
|
28234925 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tivozanib diminished GBM cell invasion through impairing the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).
|
28287096 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus preclinical validation of molecular interaction between diosgenin and NFE2L2 down-regulating MMP-2, EMT markers and promoting apoptosis, offers rationale for new therapeutic horizons in the field of glioblastoma management.
|
30885764 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment could target the Matrix metalloproteinase-2 (MMP-2), which is known to be involved in the invasion process of glioblastoma cells.
|
27678152 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, our data suggest that MMP2 and E-cadherin, a key factor in epithelial-mesenchymal transition (EMT), are involved in the miR-633/TGF-β1-mediated metastasis of glioblastoma.
|
26717894 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among these MMPs, gelatinases (MMP-2 and MMP-9) and its activator MMP-14 are known to play a key role in tumour angiogenesis and the growth of many cancers such as glioblastoma multiforme (GBM), an aggressive malignant tumour of the brain.
|
29338907 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor growth rate and final tumor weight were significantly increased in the animals with the glioblastoma derived from transfected U87-H4645 cells, compared to untransfected and vector control (p<0.01). mRNA expression of β-catenin, CD44, ICAM-1, and MMP-2 in the glioblastoma derived from the transfected U87-H4645 tumors was significantly increased compared with tumors derived from untransfected and vector-control U87 cells (p<0.01).
|
29848673 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consistent with this idea, 39% less extracellular MMP2 was measured from knockdown cells identifying one mechanism by which calpain 2 mediates glioblastoma cell invasion.
|
20730561 |
2010 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that VEGFa may regulate MMP2 in glioblastoma, while MMP2 did not appear to affect VEGFa levels.
|
25213694 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
GBM cell lines capable of forming caveolae expressed more uPA and matrix metalloproteinase-2 (MMP-2) and/or -9 (MMP-9) and were more invasive than GBM cells devoid of caveola-forming proteins.
|
30949900 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further elucidate the effects of inhibition of ECM remodeling-related enzymatic activity (Matrix metalloproteinase (MMP) 2/9, hyaluronan synthase (HAS)) on GBM cell invasion.
|
29545552 |
2018 |